This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AM803
Description: AM803 binds to FLAP, inhibiting the synthesis of leukotrienes that cause inflammation. FLAP is a key component early in the leukotriene pathway, a complex signaling process that exerts control over biological processes, such as inflammation and immunity. Excessive activity of FLAP exacerbates inflammatory diseases, such as asthma; the FLAP gene has also been linked to a significant increase in the risk of myocardial infarction and stroke.
Deal Structure: In February 2008, Amira Pharmaceuticals and GlaxoSmithKline today they have entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein) inhibitors for the treatment of respiratory and cardiovascular disease. Under the terms of the agreement GSK will be granted an exclusive, worldwide license to develop, manufacture and commercialize Amiras FLAP inhibitors. In the event that all potential development and regulatory milestones are successfully achieved, Amira could receive up to US $425 million in upfront and milestone payments. In addition, Amira will be entitled to receive tiered royalty payments based on worldwide net sales and commercial sales milestones.
In June 2008, Amira Pharmaceuticals announced that under the terms of a worldwide exclusive agreement entered into in February 2008, GlaxoSmithKline (GSK) will exercise its right to a second FLAP compound, AM803.
In July 2011, Bristol-Myers Squibb Company...See full deal structure in Biomedtracker
Partners: FLAP, LLC
Additional information available to subscribers only: